More uncertainty has roiled Teva, as the company indicated it would eliminate up to 350 production workers in Israel.

Endo has decided the 350 jobs it whacked from its Huntsville, Alabama, manufacturing site were not enough and will close it instead.

Corning, with input from Pfizer and Merck, intends to build a $500 million plant in the U.S. to produce a new pharma glass.

Australia’s TPI Enterprises has struck a deal to buy the opioid and CMO tablet businesses of Norway’s Vistin Pharma.

GlaxoSmithKline plans to unload some marginal businesses and make other cuts that it says will cost about 320 manufacturing jobs in its home country.

The FDA has warned the maker of an OTC oral rinse product to stop manufacturing it on the same equipment it uses to produce a car polish.

India’s Alembic Pharma said the facility will manufacture 60 million tablets and capsules and about 20 million vials of liquid concentrates.

Baxter Pharmaceutical is voluntarily recalling sodium chloride dextrose units due to a lack of assurance of sterility and the possibility of leakage.

Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.